Zamagni E.; Patriarca F.; Nanni C.; Zannetti B.; Englaro E.; Pezzi A.; Tacchetti P.; Buttignol S.; Perrone G.; Brioli A.; Pantani L.; Terragna C.; Carobolante F.; Baccarani M.; Fanin R.; Fanti S.; Cavo M., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, «BLOOD», 2011, 118, pp. 5989 - 5995 [Scientific article]
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study., «THE LANCET», 2010, 376, pp. 2075 - 2085 [Scientific article]
Terragna C.; Remondini D.; Martinelli G.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Brioli A.; Ceccolini M.; Testoni N.; Marzocchi G.; Castellani G.; Durante S.; Di Raimondo F.; Patriarca F.; Catalano L.; Masini L.; Ledda A.; Angelucci E.; Galieni P.; Gozzetti A.; Baccarani M.; Cavo M., CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS, in: Haematologica, «HAEMATOLOGICA», 2010, 95[suppl.2], pp. 214 - 214 (atti di: 15th Congress of the European Hematology Association, June 10-13, 2010, Barcelona, Spain, June 10 - 13, 2010;) [Abstract]
Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M., Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency., «BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION», 2010, 16, pp. 1115 - 1121 [Scientific article]
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M, Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2010, 84, pp. 484 - 492 [Scientific article]
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M., Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma., «JOURNAL OF CLINICAL ONCOLOGY», 2009, 27(30), pp. 5001 - 5007 [Scientific article]
Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S., Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types., «CIRCULATION», 2009, 13, pp. 1203 - 1212 [Scientific article]
Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P., Thalidomide maintenance in multiple myeloma: certainties and
controversies., «JOURNAL OF CLINICAL ONCOLOGY», 2009, 27(32), pp. 186 - 187 [Comment or similar]
Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.; Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M., The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation, «HEMATOLOGY MEETING REPORTS», 2009, 3, pp. 24 - 25 [Scientific article]
Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M., Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2008, 80, pp. 31 - 36 [Scientific article]
Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M., Proteasome inhibitors: Bortezomib in multiple myeloma, «HEMATOLOGY MEETING REPORTS», 2008, 2, pp. 127 - 132 [Scientific article]
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S., 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone., «IN VIVO», 2008, 22, pp. 513 - 517 [Scientific article]
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma., «HAEMATOLOGICA», 2007, 92(1), pp. 50 - 55 [Scientific article]
C. Terragna; M. Renzulli; D. Remondini; E. Tagliafico; E. Roncaglia; P. Tosi; E. Zamagni; P. Tacchetti; G. Perrone; M. Ceccolini; G. Martinelli; M. Baccarani; M. Cavo, Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM, in: , «BLOOD», 2007, 108(atti di: 48th American Society for Hematology Annual Meeting, Orlando, Florida, December 9-12, 2006) [Abstract]
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA., Neuropathy in multiple myeloma treated with thalidomide: a prospective study., «NEUROLOGY», 2007, 69, pp. 573 - 581 [Scientific article]
